If you purchased or acquired securities in AstraZeneca between between February 23, 2022 and December 17, 2024 and would like ...

The AstraZeneca PLC ADR AZN slipped 1.27% to $69.86 Monday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite Index COMP falling 1.20% to ...

Britain on Monday hit back at AstraZeneca over the collapse of a 450 million pound ($558.5 million) investment, saying the drugmaker had scaled back the research and development portion of its plans, ...

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Astrazeneca (AZN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the ...

Angle (LON:AGL) is a small share that's skyrocketed in recent weeks. Why does this investor hold the high-risk penny stock?

(Alliance News) - AstraZeneca PLC on Monday said Imfinzi has been recommended for approval in the EU as monotherapy for limited-stage small cell lung cancer.

XTB analyst Kathleen Brooks commented: "The Bank of England is expected to cut interest rates, and the US NFP report for January is expected to report a sharp slowdown in job creation." Here is what ...

For the first half of the fiscal year, analysts anticipate organic sales growth of 0.5%, net sales of $10.7bn and a 2% ...

Explore the key catalysts for the FTSE 100 index in the coming week, including the Bank of England decision and key earnings.

AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...

AstraZeneca AZN will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks Consensus ...

Flagship Harbor Advisors LLC lowered its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 2.5% during the 4th ...